320 related articles for article (PubMed ID: 16959680)
1. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
2. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
[TBL] [Abstract][Full Text] [Related]
3. Are the available low-molecular-weight heparin preparations the same?
Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
[TBL] [Abstract][Full Text] [Related]
5. Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin).
Fareed J; Walenga JM; Hoppensteadt D; Borris LC; Lassen MR
Semin Thromb Hemost; 1991; 17 Suppl 3():319-28. PubMed ID: 1661440
[TBL] [Abstract][Full Text] [Related]
6. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin.
Jeske W; Fareed J; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Semin Thromb Hemost; 1997; 23(2):119-28. PubMed ID: 9200335
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin.
Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Semin Thromb Hemost; 1995; 21(2):212-27. PubMed ID: 7660144
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins: are they different?
Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
[TBL] [Abstract][Full Text] [Related]
10. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard.
Sié P; Aillaud MF; de Prost D; Droullé C; Forestier F; Guedj P; Juhan-Vague I; Polack B; Potron G; Roncato M
Thromb Haemost; 1987 Oct; 58(3):879-83. PubMed ID: 2829376
[TBL] [Abstract][Full Text] [Related]
11. [Comparative evaluation of unfractionated and low molecular weight heparins. Results of the French Etalonorme interlaboratory quality control].
Houbouyan LL; Goguel AF
Ann Biol Clin (Paris); 1993; 51(2):109-17. PubMed ID: 8214808
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of anticoagulant activity for low molecular-weight heparin by chromogenic substrate. Measurement of factor Xa and thrombin activities].
Ishimitsu S; Sugiyama T; Itoh M; Natsuga T; Komatsu H; Okada S
Yakugaku Zasshi; 1994 Aug; 114(8):611-7. PubMed ID: 7932105
[TBL] [Abstract][Full Text] [Related]
13. Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity.
Palm M; Mattsson C; Svahn CM; Weber M
Thromb Haemost; 1990 Aug; 64(1):127-32. PubMed ID: 2177229
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.
Frydman A
Haemostasis; 1996; 26 Suppl 2():24-38. PubMed ID: 8707165
[TBL] [Abstract][Full Text] [Related]
15. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins.
Fareed J; Walenga JM; Racanelli A; Hoppensteadt D; Huan X; Messmore HL
Haemostasis; 1988; 18 Suppl 3():33-47. PubMed ID: 2840373
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man.
Wolzt M; Eder M; Weltermann A; Entlicher J; Eichler HG; Kyrle PA
Thromb Haemost; 1997 Aug; 78(2):876-9. PubMed ID: 9268188
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of reviparin-sodium.
Hoppensteadt D; Jeske W; Fareed J
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S11-6. PubMed ID: 8180323
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies on a low molecular weight heparin.
Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Thromb Res; 1996; 81(2 Suppl):S1-27. PubMed ID: 8822124
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic profile of a low-molecular-weight heparin depolymerized by gamma-irradiation.
Jeske W; Iqbal O; Gonnela S; Boveri G; Torri G; De Ambrosi L; Fareed J
Semin Thromb Hemost; 1995; 21(2):201-11. PubMed ID: 7660143
[TBL] [Abstract][Full Text] [Related]
20. [Low molecular weight heparin fractions. Comparative preclinical study of various parameters].
Fareed J
J Mal Vasc; 1987; 12 Suppl B():59-63. PubMed ID: 2834492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
